Impact of hemodialysis combined with hemoperfusion on metabolism, cytokines, and novel biomarkers in chronic kidney disease patients
Journal of Medical Biochemistry · 2026 · (00) · 119-119
DOI: 10.5937/jomb0-63909 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Biochemistry, 2026. Verfasst von Nijun Zheng und 5 weiteren Autor:innen. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Chronic kidney disease (CKD) often progresses to end-stage renal disease (ESRD), severely affecting patients' lives. This article explored the effects of hemodialysis (HD) combined with hemoperfusion (HP) on metabolic indicators, inflammatory cytokines, and novel biomarkers - including oxidative stress markers (malondialdehyde, MDA; superoxide dismutase, SOD), vascular endothelial markers (endothelin-1, ET-1), fibrosis markers (transforming growth factor-betal, TGF-β1), and metabolic risk markers (homocysteine, Hcy) - in CKD patients.
Methods
A retrospective analysis was conducted on clinical data from 72 CKD patients admitted to Changxing County Hospital of Traditional Chinese Medicine from October 2023 to October 2025. Patients were divided into the HD+HP group (AG, n=35) and the HD group (BG, n=37). Changes in metabolic indicators, inflammatory factors, and novel biomarkers were compared before and after 6 months of treatment.
Results
After treatment, the AG showed markedly lower levels of BUN, Scr, iPTH, and β2-MG compared to the BG (P<0.05), with a 42.3% reduction in iPTH (326.7±58.4 pg/mL vs. 566.2±89.1 pg/mL). The AG also had markedly lower levels of IL-6, TNF-α, and hs-CRP (P<0.01). Novel biomarkers, including MDA, ET-1, TGF-β1, and Hcy, were significantly lower in AG post-treatment (P<0.05), while SOD activity was significantly increased. No visible distinction was noted in adverse event rates (P>0.05).
Conclusion
HD combined with HP can more effectively remove mediumand large-molecular-weight toxins, improve oxidative stress, endothelial function, and fibrosis markers, and markedly improve calcium-phosphorus metabolism disorders and micro-inflammatory status, providing comprehensive clinical evidence for optimizing blood purification strategies.
Zitieren
APA
Zheng, N., Yan, X., Lu, H., Song, T., Zhao, J., & Cai, M. (2026). Impact of hemodialysis combined with hemoperfusion on metabolism, cytokines, and novel biomarkers in chronic kidney disease patients. Journal of Medical Biochemistry, 119-119. https://doi.org/10.5937/jomb0-63909
Vancouver
Zheng N, Yan X, Lu H, Song T, Zhao J, Cai M. Impact of hemodialysis combined with hemoperfusion on metabolism, cytokines, and novel biomarkers in chronic kidney disease patients. Journal of Medical Biochemistry. 2026:119-119. doi:10.5937/jomb0-63909
BibTeX
@article{Zheng2026,
author = {Zheng, Nijun and Yan, Xuepeng and Lu, Haitao and Song, Tonghe and Zhao, Jixiang and Cai, Ming},
title = {Impact of hemodialysis combined with hemoperfusion on metabolism, cytokines, and novel biomarkers in chronic kidney disease patients},
journal = {Journal of Medical Biochemistry},
year = {2026},
number = {00},
pages = {119--119},
doi = {10.5937/jomb0-63909}
}
EUVIMED